Παρά τη συστηματική δυσφήμιση των mRNA εμβολίων από τους αντιεμβολιαστές ως πειραματικά, φαίνεται ότι οι επόμενες γενεές θα έχουν στη διάθεση τους μια επαναστατική τεχνολογία έναντι των λοιμώξεων:
Ολόκληρο το άρθρο εδώ: https://arstechnica.com/science/2021/07 ... has-begun/The mRNA-based vaccine strategy offers a highly precise way to target influenza viruses' HA and NA compared with current flu vaccines, which often rely on presenting whole viruses, weakened or inactivated, to the immune system. And the mRNA-based design makes the vaccines easy to tweak. If, for instance, a flu virus appears one season with a slightly different version of HA—as it very often does—the vaccine's coding would potentially take just an update to tailor that year's shot. This is a change that could potentially be done swiftly, too.
When variants of SARS-CoV-2 began raising concern earlier this year, the CEO of BioNTech—which co-developed an mRNA-based COVID-19 with Pfizer—said the company could adjust its mRNA vaccine in just six weeks, if needed.
Perhaps the biggest advantage the mRNA-based strategy has over current flu vaccines, though, is that it doesn't involve eggs. Current flu vaccines are most often manufactured using fertilized hen eggs. Vaccine-makers inject the virus into the eggs and allow the virus to create legions of clones. Then, vaccine-makers harvest the viruses, purify them, weaken or kill them, and use them for vaccines. It's cheap and simple, and it's a method that has been used for decades.
But it's also time consuming, it requires a lot of eggs, and it may not produce high-efficacy vaccines. Weak or inactivated virus vaccines lack the precision of other vaccine strategies, like mRNA or recombinant proteins. With a whole virus, the immune system may try to attack many different features of the virus, some of which may not be very useful for thwarting the invader.
